A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
A Multicenter, Open-Label, Non-Randomized, Single-Arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia/Lymphoma
This is a clinical research study for people with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoma.
The study will test a new treatment called "autologous nano CD5-CAR T cells". These are your own immune cells that have been changed in a lab to recognize and kill cancer cells.
This study has two parts: Phase 1 to test the safety and best dose of the treatment, and Phase 2 to see how well it works.
You may receive the study treatment if you meet all the eligibility criteria. The main things the study will look at are: how safe the treatment is, how many people's cancer goes away or gets better, and how long the effect lasts.
Possible risks include fever, low blood pressure, and infection, which the study team will monitor closely.
연구 개요
상태
상세 설명
This is a multicenter, open-label, non-randomized, single-arm Phase 1/2 study evaluating the safety and efficacy of autologous nano CD5-CAR T cells in adult and adolescent patients with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) who have failed prior standard therapies.
The Phase 1 portion uses a dose-escalation design to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). The Phase 2 portion will enroll patients at the RP2D to evaluate the overall response rate (ORR) per independent review committee (IRC) assessment.
Secondary objectives include assessment of duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety profile including adverse events (AEs) of special interest such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
Key inclusion criteria include confirmed diagnosis of r/r T-ALL/T-LBL, adequate organ function, and measurable disease. Key exclusion criteria include active severe infection, prior allogeneic stem cell transplantation within 100 days, and known central nervous system involvement that is not controlled.
The study will enroll approximately [X] patients at multiple investigational sites in China. All patients will receive lymphodepleting chemotherapy followed by infusion of autologous nano CD5-CAR T cells. Safety assessments will be performed throughout the study period, including regular laboratory tests and clinical evaluations.
연구 유형
등록 (추정된)
단계
- 2 단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: liang Huang
- 전화번호: +86 022-23608126
- 이메일: huangliang@ihcams.ac.cn
참여기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Age 3 to 70 years old
- Diagnosed with CD5-positive relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL)
- ECOG performance status 0-2
- Adequate organ function (renal, hepatic, cardiac, pulmonary)
- Able to understand and sign informed consent
Exclusion Criteria:
- Active severe infection or uncontrolled sepsis
- History of allogeneic stem cell transplantation within 3 months
- Severe autoimmune disease or immunodeficiency
- Prior CD5-targeted therapy
- Pregnant or breastfeeding women
- Any condition that, in the investigator's opinion, would compromise safety or compliance with the protocol
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Autologous Nano CD5-CAR T Cells for Relapsed/Refractory T-ALL/LBL
All enrolled patients will receive lymphodepleting chemotherapy with fludarabine (30 mg/m²/day for 3 days) and cyclophosphamide (250 mg/m²/day for 3 days), followed by a single intravenous infusion of autologous nano CD5-CAR T cells.
The study uses a dose-escalation design with two main dose levels: 1.0×10^6 cells/kg and 2.0×10^6 cells/kg, with a backup low dose of 0.5×10^6 cells/kg.
|
Autologous CD5-targeted CAR-T cells engineered with a novel nano antibody-based chimeric antigen receptor.
Patients receive lymphodepleting chemotherapy (fludarabine 30 mg/m²/day + cyclophosphamide 250 mg/m²/day for 3 days) followed by a single intravenous infusion of CAR-T cells.
The study uses a dose-escalation design with two main dose levels: 1.0×10^6 cells/kg and 2.0×10^6 cells/kg, with a backup low dose of 0.5×10^6 cells/kg for use in case of insufficient cell yield.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of Dose-Limiting Toxicities (DLT)
기간: 28 days after CAR-T cell infusion
|
Proportion of patients experiencing dose-limiting toxicities (DLT) within 28 days after CAR-T infusion, to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D).
|
28 days after CAR-T cell infusion
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- IIT2026011
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
T 세포 급성 림프 구성 백혈병에 대한 임상 시험
-
University of Alabama at Birmingham종료됨역형성 대세포 림프종 | 혈관면역모세포성 T세포 림프종 | 말초 T 세포 림프종 | 성인 T 세포 백혈병 | 성인 T 세포 림프종 | 상세불명의 말초 T 세포 림프종 | T/Null Cell 전신형 | 림프절/내장 질환을 동반한 피부 T세포 림프종미국
Autologous nano CD5-CAR T Cells에 대한 임상 시험
-
Zhejiang UniversityShanghai YaKe Biotechnology Ltd.모병
-
Zhejiang UniversityShanghai YaKe Biotechnology Ltd.모병
-
Xuanwu Hospital, BeijingBaoding Children's Hospital모병
-
Beijing GoBroad HospitalThe General Hospital of Western Theater Command; First Affiliated Hospital of Guangxi Medical... 그리고 다른 협력자들모병급성 림프구성 백혈병, 재발 | 난치성 급성 림프구성 백혈병 | T세포 급성림프구성백혈병 | T세포 악성종양중국
-
Beijing GoBroad HospitalThe General Hospital of Western Theater Command; First Affiliated Hospital of Guangxi Medical... 그리고 다른 협력자들모병급성 림프구성 백혈병, 재발 | 난치성 급성 림프구성 백혈병 | T세포 급성림프구성백혈병 | T세포 악성종양중국
-
iCell Gene TherapeuticsPeking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.모병
-
Beijing GoBroad HospitalRuijin Hospital; Shanghai Liquan Hospital모병
-
Peking University People's HospitalHebei Senlang Biotechnology Inc., Ltd.모병전구체 T세포 림프구성 백혈병-림프종 | 태평양 표준시 | T- 세포 림프종중국
-
Essen Biotech모병T 세포 림프종 | T세포 전림프구성 백혈병 | T 세포 급성 림프 구성 백혈병 | T 세포 백혈병 | CNS의 T세포 림프종 | T 세포 유년기 ALL중국
-
Baylor College of MedicineNational Cancer Institute (NCI); The Methodist Hospital Research Institute; Center for Cell...모병T 세포 급성 림프 구성 백혈병 | T 세포 급성 림프구성 림프종 | T-비호지킨 림프종미국